详情页 - 四川省肿瘤医院知识库

当前位置：首页 > 详情页

Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients

文献详情

资源类型：

Pubmed体系：

作者：

机构： [1]Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China. [2]Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [3]Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [4]Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [5]Center for Epithelial and Airway Biology and Regeneration, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [6]Institute for Airway Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

出处：

DOI：

ISSN：

关键词： competing risk analysis oncocytic carcinoma of the thyroid neck dissection radioactive iodine survival analysis

摘要：

Oncocytic carcinoma of the thyroid (OCA) is an independent type of thyroid cancer. Radioactive iodine (RAI) therapy was frequently administered to OCA patients, but its contribution to improving survival is indefinite.4641 OCA patients from 2000 to 2018 were identified from the Surveillance, Epidemiology, and End Results (SEER) database. Cox proportional hazard regression and competing risk analysis were applied.Tumor size, SEER stage, primary surgery, and neck dissection were prognostic factors for cancer-specific survival. The results of competing risk analysis demonstrated that age over 55 years dramatically increased non-OCA death risks. Treatments that improve non-OCA survival (including total thyroidectomy, RAI therapy, and systemic therapy) should be recommended in OCA patients older than 55 years of age. Neck lymphadenectomy should not be recommended for OCA, since the metastatic lymph node ratio was low (about 3%).RAI therapy can improve survival in OCA by reducing noncancer death risks.© 2024 The Authors. Head & Neck published by Wiley Periodicals LLC.

语种：

PubmedID：

中科院(CAS)分区：

出版当年[2023]版：

大类 | 3 区医学

小类 | 3 区耳鼻喉科学 3 区外科

最新[2023]版：

大类 | 3 区医学

小类 | 3 区耳鼻喉科学 3 区外科

第一作者：

第一作者机构： [1]Division of Thyroid Surgery, Department of General Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China.

通讯作者：

通讯机构： [2]Department of Otolaryngology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [3]Department of Cell, Developmental, and Regenerative Biology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [4]Black Family Stem Cell Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [5]Center for Epithelial and Airway Biology and Regeneration, Icahn School of Medicine at Mount Sinai, New York, New York, USA. [6]Institute for Airway Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

推荐引用方式(GB/T 7714)：

APA：

MLA：

Radioactive iodine therapy improves overall survival outcome in oncocytic carcinoma of the thyroid by reducing death risks from noncancer causes: A competing risk analysis of 4641 patients

文献详情

相关文献